 LAVAL, QC and CAMBRIDGE, England, Oct. 15, 2021 PRNewswire - Liminal BioSciences Inc. Nasdaq: LMNL Liminal BioSciences or the Company, announced today that it has closed on the sale of the remainder of the Companys plasma-derived therapeutics business the Second Closing under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A. Kedrion. 